Sanofi

ENXTPA:SAN Lagerbericht

Marktkapitalisierung: €89.4b

Sanofi Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Sanofi wird ein jährliches Gewinn- und Umsatzwachstum von 19.1% bzw. 4.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 20.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 14.4% betragen.

Wichtige Informationen

19.1%

Wachstumsrate der Gewinne

20.37%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum17.8%
Wachstumsrate der Einnahmen4.3%
Zukünftige Eigenkapitalrendite14.38%
Analystenabdeckung

Good

Zuletzt aktualisiert16 Sep 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Neues Narrative • Sep 10

Sanofi stocks will shine with an 8% profit surge

Der französische Pharmariese Sanofi bietet Anlegern derzeit eine interessante Kombination aus attraktiver Bewertung, starker Dividendenrendite und solider operativer Dynamik. ​Attraktive Bewertung und Kursrücksetzer Die Aktie hat in den vergangenen Monaten nachgegeben und bewegt sich im Bereich von rund 76 bis 77 EUR.
Narrative-Update • Sep 03

SAN: Pipeline Progress And Risk Assumptions Will Shape Future Share Support

The analyst price target for Sanofi has shifted from €82.00 to €78.00. Analysts attribute the change to updated assumptions for revenue growth, profit margins, discount rate and future P/E.
Narrative-Update • Aug 20

SAN: Future Upside Will Hinge On Pipeline Execution And Margin Resilience

Sanofi's updated analyst price target has edged lower to about €94 from roughly €97, with analysts pointing to slightly softer revenue growth assumptions, a marginally higher discount rate and a lower future P/E multiple, partly offset by a modestly higher profit margin outlook. Analyst Commentary Recent commentary on Sanofi sits against a backdrop of higher target prices across parts of the European market, with several banks seeing room for upside in other large cap stocks.
Narrative-Update • Aug 05

SAN: Vaccine Approvals And Pipeline Decisions Will Support Future Upside

Analysts have raised their fair value estimate for Sanofi from €107.20 to €112.00. This change reflects updated views that include slightly lower revenue growth assumptions, a modestly higher profit margin profile, and a small adjustment to the future P/E multiple.
Narrative-Update • Jul 22

SAN: New Drug Approvals And AI Discovery Partnership Will Support Future Upside

Sanofi's updated analyst price target has shifted from €112.00 to €107.20, reflecting revised assumptions around discount rates, revenue growth, profit margins and future P/E. Analysts view these changes as better aligning the stock's valuation with current fundamentals.
Narrative-Update • Jul 02

SAN: Pipeline Approvals And R&D Execution Will Shape Future Share Support

Analysts have lifted the indicative fair value for Sanofi to €82.00 from €72.40, citing updated assumptions for revenue growth, profit margins and future P/E that are broadly in line with recent upward revisions to price targets seen across parts of the European market. Analyst Commentary Analysts covering Sanofi have framed the updated fair value in the context of broader reassessments across European equities, with the new €82.00 level positioned as an attempt to reflect current assumptions on growth, profitability and P/E multiples rather than a shift driven by any single catalyst.
Narrative-Update • Jun 18

SAN: Future Upside Will Hinge On AI Execution Across R&D Workflows

Sanofi's analyst price target has been revised slightly to €96.70 from €97.10. This change reflects updated views on its revenue growth outlook, profit margin assumptions and a modestly adjusted future P/E multiple, according to recent analyst commentary.
Narrative-Update • Jun 04

SAN: Future Upside Will Depend On AI Execution And R&D Pipeline Delivery

Analysts have nudged their fair value estimate for Sanofi higher from €95.53 to €97.10, citing slightly adjusted assumptions on discount rate, revenue growth, profit margins and future P/E as the basis for the updated price target. Analyst Commentary Bullish analysts framing the updated fair value for Sanofi around €97.10 are effectively signaling confidence that the company can execute in line with, or slightly ahead of, their refined assumptions on discount rate, revenue trajectory, margins and implied future P/E.
Analyseartikel • May 04

Sanofi's (EPA:SAN) Conservative Accounting Might Explain Soft Earnings

Shareholders appeared unconcerned with Sanofi's ( EPA:SAN ) lackluster earnings report last week. We think that the...
Narrative-Update • Apr 22

SAN: Future Upside Will Rely On Pipeline Delivery And Margin Execution

Sanofi's analyst price target has been adjusted slightly lower to €95.53 from €96.10, as analysts factor in marginally higher revenue growth expectations, a modestly lower profit margin and a revised forward P/E assumption. Analyst Commentary Recent Street research on large European financials and cross border bank transactions offers a useful lens for thinking about how analysts might be framing Sanofi's current valuation reset and execution risks, even though the specific notes focus on banks rather than pharmaceuticals.
Neues Narrative • Apr 14

Pipeline And Vaccine Catalysts Will Reshape This Pharma Leader Over The Next Decade

Catalysts About Sanofi Sanofi is a global biopharma group focused on prescription medicines, vaccines and specialty care therapies. What are the underlying business or industry changes driving this perspective?
Narrative-Update • Apr 07

SAN: Future Upside Will Rely On Pipeline Delivery And Margin Expansion

Analysts trimmed Sanofi's fair value estimate by €2.00 to €96.10, citing updated assumptions that include slightly different revenue growth, a higher profit margin profile, and a lower future P/E multiple. Analyst Commentary Recent Street research on European financials and cross border bank deals offers some reference points that investors can use when thinking about Sanofi's updated fair value and how sentiment can swing as assumptions change.
Neues Narrative • Mar 31

Rising R&D Burden And Pipeline Risk Will Challenge Long Term Profitability

Catalysts About Sanofi Sanofi is a global biopharmaceutical company focused on prescription medicines, vaccines and specialty care therapies. What are the underlying business or industry changes driving this perspective?
Narrative-Update • Mar 24

SAN: Future Upside Will Rely On Pipeline Execution And Margin Strength

Sanofi's analyst price target has been adjusted to €98.10 from €98.49 as analysts factor in slightly higher assumed revenue growth, stronger profit margins and a lower future P/E multiple in their updated models. Analyst Commentary Analysts updating their models for Sanofi are weighing the slightly higher revenue assumptions and stronger margin profile against a more conservative future P/E multiple.
Narrative-Update • Mar 09

SAN: Future Upside Will Rely On Pipeline Execution And Margin Resilience

Analysts have nudged their price target on Sanofi higher to €98.49, reflecting slightly firmer revenue growth assumptions and a nearly unchanged long-term profit margin and P/E outlook. Analyst Commentary Analysts covering Sanofi are broadly focused on how the updated €98.49 price target lines up with the company’s ability to execute on its plan, sustain its profit profile and justify its current P/E.
Narrative-Update • Feb 23

SAN: Future Upside Will Rely On Pipeline Delivery And Margin Stability

Analysts have trimmed their Sanofi price target slightly to €98.49. The change is tied to more cautious assumptions for revenue growth, profit margins and a modestly higher future P/E multiple.
Narrative-Update • Feb 09

SAN: Future Upside Will Depend On Pipeline Execution And Margin Resilience

Analysts have trimmed their Sanofi price targets slightly, with fair value moving from about €101 to about €99 as they factor in a modestly higher discount rate, slightly softer revenue growth assumptions around 3.6% and a marginally lower expected profit margin near 19.7%, paired with a future P/E closer to 12.8x. Analyst Commentary Recent updates to Sanofi valuation assumptions, including a modestly higher discount rate and slightly softer revenue and margin expectations, have led analysts to fine tune their views rather than overhaul them.
Narrative-Update • Jan 25

SAN: Future Upside Will Depend On Pipeline Approvals And Margin Discipline

Analysts have trimmed their price target on Sanofi to reflect a fair value move from €102.77 to €100.96, citing updated assumptions around revenue growth, profit margins and future P/E levels. Analyst Commentary While the latest fair value trim for Sanofi is modest, it still reflects a tight range of outcomes that analysts see as reasonable based on current assumptions around growth, profitability and P/E levels.
Narrative-Update • Jan 11

SAN: Future Upside Will Depend On Pipeline Approvals And Margin Discipline

Analysts have trimmed their fair value estimate for Sanofi from about €104.87 to roughly €102.77, pointing to slightly softer assumptions for revenue growth, profit margins and future P/E as key drivers of the updated price target outlook. Analyst Commentary Recent fair value adjustments for Sanofi sit against a backdrop of active price target revisions across European equities, including large financials, where several research desks have been updating their expectations.
Narrative-Update • Dec 25

SAN: Future Upside Will Depend On Pipeline Delivery And Cost Discipline

Analysts have trimmed their price target for Sanofi modestly, cutting their fair value estimate by about EUR 0.33 to roughly EUR 104.87. They cite slightly slower revenue growth, a softer profit margin profile, and a marginally higher future earnings multiple as the main factors behind this adjustment.
Narrative-Update • Dec 11

SAN: Future Returns Will Depend On Execution Of Late-Stage Pipeline

Analysts have nudged their fair value estimate for Sanofi slightly lower from EUR 106.26 to about EUR 105.20, citing marginally softer revenue growth assumptions, partially offset by a modestly stronger profit margin outlook and a slightly reduced forward P E multiple. Analyst Commentary Analyst sentiment on Sanofi remains broadly constructive, with recent fair value adjustments reflecting a more nuanced balance between growth ambitions and execution risks.

Gewinn- und Umsatzwachstumsprognosen

ENXTPA:SAN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/202853,16710,30910,05814,16411
12/31/202750,6448,8869,00812,93612
12/31/202647,6487,4798,30612,55712
6/30/202648,9193,9398,42411,838N/A
3/31/202647,3544,8296,80210,340N/A
12/31/202546,7164,9397,21210,750N/A
9/30/202545,9316,4307,92111,116N/A
6/30/202545,7386,3838,40311,214N/A
3/31/202545,1666,2187,89111,086N/A
12/31/202444,2865,4965,8869,081N/A
9/30/202448,4454,506N/AN/AN/A
6/30/202439,5473,6764,3378,117N/A
3/31/202446,2884,538N/AN/AN/A
12/31/202341,1095,0627,35210,258N/A
9/30/202345,6999,066N/AN/AN/A
6/30/202346,0458,6178,10710,264N/A
3/31/202346,1998,357N/AN/AN/A
12/31/202240,3047,9708,42310,526N/A
9/30/202244,3486,409N/AN/AN/A
6/30/202242,0396,6437,5949,620N/A
3/31/202240,3426,666N/AN/AN/A
12/31/202139,1756,2238,47910,522N/A
9/30/202138,4966,174N/AN/AN/A
6/30/202137,5465,7775,8278,219N/A
3/31/202136,93912,197N/AN/AN/A
12/31/202037,36912,2945,3357,418N/A
9/30/202037,65011,224N/AN/AN/A
6/30/202037,69211,1386,8348,491N/A
3/31/202038,2343,453N/AN/AN/A
12/31/201937,6312,855N/A7,715N/A
9/30/201936,9403,179N/AN/AN/A
6/30/201936,7633,591N/A6,953N/A
3/31/201936,2644,439N/AN/AN/A
12/31/201835,6774,319N/A5,547N/A
9/30/201835,3164,041N/AN/AN/A
6/30/201834,9853,243N/A6,596N/A
3/31/201835,4283,539N/AN/AN/A
12/31/201736,2213,773N/A7,379N/A
9/30/201736,4004,593N/AN/AN/A
6/30/201736,3154,744N/A8,133N/A
3/31/201735,6774,682N/AN/AN/A
12/31/201634,6964,395N/A7,838N/A
9/30/201634,3494,195N/AN/AN/A
6/30/201634,1154,154N/A8,122N/A
3/31/201634,5694,440N/AN/AN/A
12/31/201534,8614,411N/A8,920N/A
9/30/201537,2015,292N/AN/AN/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SANDas prognostizierte Gewinnwachstum (19.1% pro Jahr) liegt über der Sparquote (2.6%).

Ertrag vs. Markt: SANDie Erträge des Unternehmens (19.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt French (12.7% pro Jahr).

Hohe Wachstumserträge: SANDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: SANDie Einnahmen des Unternehmens (4.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt French (5.8% pro Jahr).

Hohe Wachstumseinnahmen: SANDie Einnahmen des Unternehmens (4.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: SANDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (14.4%).

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/09/21 17:07
Aktienkurs zum Tagesende2026/09/21 00:00
Gewinne2026/06/30
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.

Erfahren Sie mehr über das , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Sanofi wird von 52 Analysten beobachtet. 22 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
John EadeArgus Research Company
Odile RundquistBaader Helvea Equity Research
null nullBanco de Sabadell. S.A.